Bio-Models That Reflect Human Reality

CSTEAM develops advanced bio-models that replicate human biology with high fidelity. By integrating cellular, tissue, and microenvironmental components, our models capture complex biological interactions beyond conventional systems. Designed for predictive drug validation, they enable early assessment of efficacy, safety, and resistance. These models form a critical foundation of our platform, generating reliable, human-relevant data that bridge the gap between laboratory research and clinical outcomes, and support more accurate and confident drug development decisions.

NAMs-Aligned Organoid Standards

White Paper

(A Standardized Framework for Reproducible Human-Relevant Organoid Models)

This white paper presents a standardized framework for developing reproducible, human-relevant organoid models aligned with FDA New Approach Methodologies (NAMs). It defines clear criteria for inputs, processes, validation, and performance, with a focus on improving predictivity and decision-making in drug development. Designed for pharmaceutical companies, biotechnology firms, and research institutions, the framework addresses key challenges in variability and scalability. By integrating biological fidelity with engineering control and regulatory alignment, it provides a practical pathway to reduce risk, enhance model reliability, and accelerate the translation of organoid systems into industrial and clinical applications.

Biological Models Platform

(From Molecular to Whole-Organism Models)

d45bd3_738702dcb0d8439a965fc8e6ccd4048f~mv2.png

3D High-Throughput Micro-Chip for Organoid Culture and Drug Screening

IBAC (Integrated Biomimetic Array Chip) - S

High-Throughput Barrier Function Organ-on-Chips

IBAC (Integrated Biomimetic Array Chip) - M1

Organoid Expansion Chip for Dynamic Culture

IBAC (Integrated Biomimetic Array Chip) - 01

Organoid Expansion Chip for Dynamic Culture

IBAC (Integrated Biomimetic Array Chip) - O2

Organoids for Regenerative Medicine and Developmental Biology

Organoids are transforming regenerative medicine by providing platforms for tissue repair and organ transplantation. Liver, intestinal, and kidney organoids hold promise for treating organ failure and chronic diseases. In developmental biology, organoids mimic organogenesis, offering insights into human development and congenital disorders. These 3D structures replicate tissue architecture and function, enabling researchers to study cellular interactions and developmental pathways. Organoids bridge the gap between in vitro and in vivo models, advancing regenerative therapies and our understanding of human biology and disease. Lab-on-a-Chips, Organoids, Exosomes, RNAs

Intestinal Organoid Models

An intestinal organoid model is a 3D miniature structure derived from stem cells that mimics the intestinal epithelium's cellular organization and function. It provides a platform for studying gut development, nutrient absorption, disease mechanisms like inflammatory bowel disease and infections, and is extensively used in drug screening, microbiome research, and regenerative medicine.

(1) Pluripotent Stem Cell (PSC)-Derived Intestinal Organoids

(2) Adult Stem Cell (ASC)-Derived Intestinal Organoids

(3) Microfluidic Gut-on-a-Chip Organoids

(4) Vascularized Intestinal Organoids

(5) Gut-Brain Axis Organoids

(6) Cancer-Derived Intestinal Organoids

Organoids for Disease Modeling and Drug Development

Organoids have transformed disease modeling and drug development by replicating human tissue structure and function within a 3D environment. They enable the study of complex diseases, including cancer, genetic disorders, and infections, while providing platforms for drug screening, toxicity testing, and therapy optimization. Additionally, organoids support personalized medicine and bridge the gap between preclinical research and clinical applications, offering vast potential for future applications. Lab-on-a-Chips,

Our Services

Genetic Disease Organoids

Disease Modeling and Drug Development

Genetic disease organoids are 3D patient-derived or gene-edited models that accurately replicate the cellular architecture and genetic mutations of inherited disorders. These organoids can provide reliable disease models for studying conditions such as cystic fibrosis, muscular dystrophy, and neurodegenerative diseases, offering unprecedented insights into pathogenesis and therapeutic targets. Their integration with CRISPR gene editing, high-throughput drug screening, and omics technologies enables the development of targeted therapies and personalized medicine approaches. By bridging the gap between preclinical research and clinical applications, genetic disease organoids accelerate drug discovery, gene therapy validation, and precision medicine innovations, transforming future healthcare.

Cancer Organoids

Disease Modeling and Drug Development

Cancer organoids are 3D tumor models derived from patient biopsy samples or genetically engineered cells, replicating the heterogeneity, genetic mutations, and tumor microenvironment of real cancers. These models enable precise disease modeling, allowing researchers to study tumor initiation, progression, and resistance mechanisms. Integrated with CRISPR gene editing, high-throughput drug screening, and personalized medicine approaches, cancer organoids facilitate targeted therapy development, immunotherapy testing, and precision oncology. They bridge the gap between preclinical studies and clinical applications, accelerating the discovery of novel anticancer drugs and improving patient-specific treatment strategies, revolutionizing the future of cancer research and therapy.

Infectious Disease Organoids

Disease Modeling and Drug Development

Infectious disease organoids are 3D human tissue models that mimic host-pathogen interactions, immune responses, and infection progression in a physiologically relevant environment. These models enable researchers to study viral, bacterial, and parasitic infections, such as SARS-CoV-2, HIV, tuberculosis, and malaria. By integrating CRISPR gene editing, high-throughput drug screening, and immune cell co-culture, organoids provide insights into pathogen-host dynamics, antimicrobial resistance, and vaccine development. Their application in personalized medicine helps identify patient-specific responses to antiviral and antibiotic treatments, bridging preclinical research and clinical applications, accelerating drug discovery and therapeutic strategies for combating infectious diseases effectively.

Neurodegenerative Disease Organoids

Disease Modeling and Drug Development

Neurodegenerative disease organoids are 3D brain-like models derived from iPSCs or patient-specific stem cells, replicating neuronal architecture, synaptic connections, and disease-specific pathology. These organoids enable the study of Alzheimer’s, Parkinson’s, Huntington’s disease, and ALS, offering insights into neuronal degeneration, protein aggregation, and neuroinflammation. Integrated with CRISPR gene editing, high-throughput drug screening, and electrophysiological analysis, they facilitate the discovery of neuroprotective drugs, gene therapies, and personalized medicine approaches. By bridging preclinical and clinical research, neurodegenerative disease organoids accelerate therapeutic development, improving our understanding of disease mechanisms and advancing treatments for neurodegenerative disorders.